Summary
Follicular dendritic cells (FDC) are situated in the primary follicles of lymphoid tissues where they maintain the structural integrity of the B‐lymphocyte follicle, and help to drive immunoglobulin class‐switch recombination, somatic hypermutation and affinity maturation during the germinal centre response. FDC can also provide a reservoir for pathogens that infect germinal centres including HIV and prions. FDC express high levels of the normal cellular form of the prion protein (PrPC), which makes them susceptible to prion infection. The function of PrPC is uncertain and it is not known why FDC require such high levels of expression of a protein that is found mainly on cells of the central nervous system. In this study, the function of FDC was assessed in mice that had PrPC ablated specifically in their FDC. In mice with FDC‐specific PrPC ablation, our analysis revealed no observable deficits in lymphoid follicle microarchitecture and FDC status. No effects on FDC ability to trap immune complexes or drive antigen‐specific antibody responses and affinity maturation in B lymphocytes were observed. These data clearly demonstrate that PrPC expression is dispensable for the functional maturation of FDC and their ability to maintain antigen‐specific antibody responses and affinity maturation.
Keywords: antibody response, follicular dendritic cell, germinal centre, prion protein, spleen
Introduction
Follicular dendritic cells (FDC) are a non‐migratory, non‐phagocytic stromal cell population found in the B‐lymphocyte follicles of secondary lymphoid tissue. They form networks of long dendrites, which enable close contact with many B lymphocytes and help to maintain the structural integrity of the follicle.1 Furthermore, FDC secrete the chemokine CXCL13, which stimulates the chemotaxis of further CXCR5‐expressing B lymphocytes into the follicle.2 The FDC are thought to derive from a stromal cell precursor3,4 that develops after the arrival of B lymphocytes into the follicle5 and their induction and maintenance is dependent on B‐lymphocyte‐derived lymphotoxin and tumour necrosis factor‐α.6,7 They have recently been shown to develop from precursors that are found around blood vessels, and require lymphoid tissue inducer cells and lymphotoxin for their expansion. These characteristics allow the development of FDC‐containing ectopic lymphoid follicles outwith the lymphoid tissues during chronic inflammatory conditions.8
In addition to the development and maintenance of the follicle microarchitecture, FDC are also important in driving the germinal centre (GC) response. The FDC express complement receptors (CR1, CR2 and possibly CR3) and immunoglobulin Fc receptors (FcγRIIb and possibly FcεRII), which allow them to capture antigen in the form of immune complexes.5,9 Antigens are retained on FDC surfaces in their native states for long periods of time to aid the positive selection of high‐affinity B lymphocytes during the GC response.1,7,10–14 FDC further aid this process by up‐regulating the expression of adhesion molecules such as intercellular adhesion molecule (ICAM), vascular cell adhesion molecule (VCAM) and CD44 to facilitate interactions between B lymphocytes and the retained antigen on the FDC surface.1,12,15,16 The competitive binding to antigen on the FDC surface allows B lymphocytes with the highest affinity for the eliciting antigen to receive pro‐survival signals from FDC via B‐cell activating factor and 8D6 signalling and cytokines such as interleukin‐6 and interleukin‐15.17–20 FDC can also target low‐affinity B lymphocytes for apoptosis via their secretion of milk fat globule EGF factor 8.21
Surface proteins of FDC are also exploited by certain pathogens. This results in a reservoir of pathogen in the GC that can then spread systemically via other cells trafficking through the lymphoid tissue. For example, HIV uses CD21 expression on FDC to become trapped on their surfaces where it is then able to replicate and infect B lymphocytes.22 Prions comprise a unique group of pathogens thought to be composed solely of protein with no genetic material. Infection with prions is considered to induce a conformational change in the normal host prion protein (PrPC) to an abnormally folded, infectious form (PrPSc). Furthermore, expression of PrPC is essential for prion pathogenesis to occur.23 After peripheral exposure to some prion diseases, FDC acquire PrPSc and replicate prions, which allows subsequent neuroinvasion and fatal central nervous system disease.24,25 FDC are susceptible to infection by prions because of their expression of relatively high levels of PrPC on their surfaces.24,25
The cellular isomer of the prion protein is a host‐encoded sialoglycoprotein (encoded by the Prnp gene in mice), which is expressed predominantly on neurons but also on many other cell types, including cells of the immune system.26–29 The normal cellular function of PrPC is uncertain and three independent lines of Prnp−/− mice show normal development and have no overt neurological phenotype, suggesting that either PrPC is not an essential protein or that genetic loss of PrPC can be compensated for by other mechanisms.23,30–32 Some proposed functions of PrPC include the maintenance of circadian rhythm,33 synaptic transmission,34 anxiety modulation,35 cognition36 and seizure thresholds37 as small changes in these functions have been observed in Prnp−/− mice. PrPC has also been proposed as a signal transduction protein38,39 and has been suggested to have roles in both pro‐apoptotic signalling via an associated increase in caspase 3 activity,40 and anti‐apoptotic activity via binding to the anti‐apoptotic molecule Bcl‐2.41,42 Furthermore, PrPC expression has been reported to protect both cells of the central nervous system and those of the immune system from oxidative stress.43,44 The role of PrPC on FDC is uncertain. Therefore, in this study, mice which had PrPC expression ablated exclusively on FDC were used to determine the role of PrPC in the FDC status and the development of antigen‐specific antibody responses.
Materials and methods
Mice
The CD21‐Cre mice45 and Prnpflox/flox mice46 were generated as described previously. Each had been inbred for at least 10 generations before being bred and maintained on a Prnp−/− background.47 Prnpflox/flox mice have loxP sites flanking exon 3 of the Prnp gene, which enables Cre‐mediated excision of the Prnp open reading frame in Cre‐recombinase‐expressing cells.46 To create CD21‐CrePrnpflox/− mice a single cross between the CD21‐cre mice and the Prnpflox/flox mice was performed. All mice were maintained under specific pathogen‐free conditions. All studies using experimental mice and regulatory licences were approved by the University of Edinburgh's Ethics Review Committee and performed under the authority of a UK Home Office Project Licence within the regulations of the UK Home Office ‘Animals (scientific procedures) Act 1986’.
γ‐irradiation and bone marrow reconstitution
Bone marrow from the femurs and tibias of donor mice was prepared as single‐cell suspensions (3 × 107 to 4 × 107 viable cells/ml) in Hanks’ balanced salt solution (Invitrogen, Paisley, UK). Recipient adult (6–8 weeks old) mice were γ‐irradiated (950 rad) and 24 hr later were reconstituted with 100 μl bone marrow by injection into the tail vein. Recipient mice were used in subsequent experiments as described, 100 days after bone marrow reconstitution to allow sufficient time for the removal of long‐lived B‐lymphocyte populations and their replacement from the donor bone marrow.
Confirmation of recombination of the Prnp open reading frame by PCR analysis
DNA was prepared from peripheral blood and spleens of bone marrow‐reconstituted CD21‐CrePrnpflox/− mice using the DNeasy blood and tissue kit (Qiagen, Crawley, UK) according to the manufacturer's instructions. DNA samples were analysed for the presence of Prnp−/−, Prnpflox and recombined Prnpflox (Prnpde‐flox) using the following primers: Prnpflox Primer 1, AATGGTTAAACTTTCGTTAAGGAT; Prnpflox Primer 2, GCCGACATCAGTCCACATAG; Prnpflox Primer 3, GGTTGACGCCATGACTTTC. The PCR products were resolved by electrophoresis through a 1·0% agarose gel containing 0·002% GelRed (Biotium; Cambridge Biosciences Ltd, Cambridge, UK). Presence of Prnp−/− is indicated by a 167‐bp product, Prnpflox by a 210‐bp product and Prnpde‐flox by a 344‐bp product.
Immunohistochemistry and immunofluorescent analyses
Spleens were removed and snap‐frozen in liquid nitrogen. Serial frozen sections (8 μm in thickness) were cut on a cryostat and immunostained with the following antibodies: FDC were visualized by staining with monoclonal antibody (mAb) 7G6 to detect CR2/CR1 (CD21/CD35; BD Biosciences PharMingen, Oxford, UK), mAb FDC‐M2 to detect C4 (AMS Biotechnology, Oxon, UK) or mAb 8C12 to detect CR1 (CD35; BD Biosciences PharMingen). PrPC was detected using the PrP‐specific 1B3 polyclonal antiserum.48 B cells were detected using mAb B220 to detect CD45R (Caltag, Towcester, UK), or anti‐CD19 (BD Biosciences PharMingen). Marginal zone B cells were detected using mAb 1B1 to detect CD1d (BD Biosciences PharMingen). T cells were detected using mAb 17A2 to detect CD3 (Cambridge Bioscience). Classical dendritic cells were detected using mAb HL3 to detect CD11c (BD Biosciences PharMingen). Mucosal vascular addressin cell adhesion molecule (MADCAM) 1‐expressing cells were detected using mAb MECA‐367 (AbD Serotec, Kidlington, UK). Expression of VCAM was detected using mAb STA to detect CD106 (Caltag). Toll‐like receptor 4 (TLR4) expression was detected using mAb 76B357.1 (Abcam, Cambridge, UK). Splenic sympathetic nerves were detected using tyrosine hydroxylase‐specific polyclonal antibody (Millipore, Watford, UK).
For light microscopy, following the addition of primary antibodies, biotin‐conjugated species‐specific secondary antibodies (Stratech, Soham, UK) were applied followed by alkaline phosphatase (AP) coupled to the avidin/biotin complex (Vector Laboratories, Peterborough, UK). Vector Red (Vector Laboratories) was used as a substrate and sections were counterstained with haematoxylin to distinguish cell nuclei. Sections were mounted in Vectamount (Vector Laboratories) and examined using a Nikon Eclipse E800 microscope (Nikon UK Ltd, Surrey, UK). For fluorescent microscopy, following the addition of primary antibody, species‐specific secondary antibodies coupled to Alexa Fluor® 488 (green), Alexa Fluor® 594 (red) or Alexa Fluor® 647 (blue) dyes (Invitrogen) were used. Sections were mounted in fluorescent mounting medium (DakoCytomation) and examined using a Zeiss LSM5 confocal microscope (Zeiss, Welwyn Garden City, UK).
Image analysis
Digital microscopy images were analysed using imagej software (http://rsb.info.nih.gov/ij/) as described.49 All images were coded and assessed blindly. Background intensity thresholds were first applied using an imagej macro that measures pixel intensity across all immunostained and non‐stained areas of the images. The obtained pixel intensity threshold value was then applied in all subsequent analyses. Next, the number of pixels of each colour (black, red, green, yellow) was automatically counted and presented as a proportion of the total number of pixels in each area under analysis. Analysis of positive labelling was used to determine the area of FDC network immunostained in each section. Spleens from six mice from each group were analysed. From each spleen, two sections were studied and on each section data from four randomly chosen fields of view over the entire section were collected. Hence, for each mouse group, data from a total of 48 individual images were analysed. To compare the number of FDC networks, the number of CD35‐immunolabelled FDC networks in two sections from each spleen from each mouse (n = 6) in each group were studied. On each of these sections the number of CD35+ FDC networks was counted in each of four randomly chosen fields of view when viewed with the ×10 objective. Hence, for each parameter tested, data from a total of 48 individual images/FDC networks were analysed/group. A one‐way analysis of variance test was then used to statistically compare data between each group.
FACS analysis
Single spleen cell suspensions were prepared and red blood cells were removed using red blood cell lysis buffer (Sigma, Poole, UK). Viable cells were counted by trypan blue‐exlusion and adjusted to 1 × 106 viable cells/50 μl in FACS buffer (PBS pH7·4 containing 0·1% BSA, 0·1% sodium azide and 0·02% EDTA). Non‐specific immunoglobulin‐binding was blocked using Seroblock FcR rat anti‐mouse CD16/32 (AbD Serotech, Kidlington, UK) and subsequently immunostained with mAb 7G6 to detect CD21/35 and PrP‐specific 1B3 polyclonal antiserum. Samples were then incubated with phycoerythrin‐conjugated and FITC‐conjugated species‐specific secondary antibodies. Appropriate non‐specific antibody isotypes were used as controls. A FACS Scan flow cytometer (Becton Dickinson, Oxford, UK) was used to analyse cells with the lymphocytes gated for forward and side scatter.
Immunizations
To assess antigen trapping by FDC in vivo, mice were passively immunized by intravenous injection with 100 μl pre‐formed peroxidase–anti‐peroxidase (PAP) immune complexes (Sigma). Spleens were removed 24 hr later and the presence of FDC‐associated immune complexes was identified by both immunohistochemistry and detection of peroxidase activity using the substrate Novared (Vector Laboratories).
To assess the ability of FDCs to induce an effective antigen‐specific B‐lymphocyte response, mice were immunized on day 0 intraperitoneally with 100 μl of 1 μg/μl dinitrophenyl–keyhole limpet haemocyanin (DNP‐KLH) in alum and given a boost with an equivalent intraperitoneal dose on day 14. Tail bleeds were taken on days 0 and 7, and mice were killed on day 21 and blood and spleens were harvested for further analysis.
ELISA for DNP‐specific serum antibodies
Sera from immunized mice were assayed using DNP‐specific ELISAs for IgM, total IgG and IgG subclasses. In brief, 96‐well flat‐bottomed Immuno‐Maxisorp plates (Nunc, Roskilde, Denmark) were coated by adding 100 μl/well of 10 μg/μl DNP‐BSA (Sigma) in PBS (pH 7·6) overnight at 4°. Plates were washed with PBS containing 0·05% Tween 20 (PBS‐Tween) and blocked with 1% BSA in PBS for 1 hr. Serum samples were diluted in block buffer (1% BSA in PBS), added in duplicate wells and incubated for 2 hr. For the determination of IgM antibodies, samples were incubated with AP‐conjugated goat anti‐mouse IgM (1/2000 dilution in PBS containing 1% BSA; Southern Biotech, Birmingham, AL) for 1 hr at room temperature. For measuring total IgG antibodies, samples were incubated with an AP‐conjugated goat anti‐mouse IgG Fc region antibody (1/2000; Southern Biotech). For the determination of IgG1, IgG2a, IgG2b and IgG3 antibody subclasses, plates were incubated with peroxidase‐labelled goat anti‐mouse IgG subclass‐specific antibodies (1 : 2000; Southern Biotech). All ELISAs were developed with Sigmafast™ p‐nitrophenyl phosphate (Sigma) and optical density at 640 nm was measured using an MRX microplate Reader (Dynatech Labs, Chantilly, VA).
Statistical analyses
Data are presented as mean ± SE. Significant differences between image analysis samples in different groups were sought by one‐way analysis of variance. Significant differences between sera ELISA samples in different groups were sought by Bonferonni analysis using the spss statistical analysis software package (SPSS Inc., Chicago, IL). Values of P < 0·05 were accepted as significant.
Results
Creation of compound transgenic mice with PrPC ablation specifically restricted to FDC
To achieve PrPC ablation specifically in FDC, CD21‐CrePrnpflox/− mice were created as described in the Materials and Methods. In these mice, Cre‐recombinase is expressed under the control of the CD21 promoter, which in the secondary lymphoid organs of mice is highly expressed by FDC and mature B lymphocytes.50,51 However, in humans, expression of CD21 has also been reported on a subpopulation of immature thymocytes,52 peripheral T lymphocytes53 and the cervical epithelium.54 In mouse, expression has been reported on mesenteric lymph node‐derived CD4+ T lymphocytes, activated granulocytes and mucosal mast cells.10,11,55 Therefore, to achieve Cre‐mediated excision of the Prnp open reading frame specifically in FDC, CD21‐CrePrnpflox/− animals were aged to 8 weeks, lethally γ‐irradiated and reconstituted with non‐Cre‐expressing bone marrow. Animals were given 100 days for reconstitution before further experimental analysis was carried out. Previous characterization of this model has shown it to be a specific and efficient model to achieve gene deletion specifically in FDC.2,7,25 PCR analysis of DNA isolated from the spleens of CD21‐CrePrnpflox/− mice revealed that Cre‐mediated DNA recombination (deletion or de‐flox) of the Prnp gene had occurred as anticipated, indicating that PrPC expression was ablated in the host‐derived, FDC‐containing stromal compartment of the spleen (Fig. 1a; presence of 344 bp ‘Prnpde‐flox’ band, lane 2). In contrast, no evidence of Cre‐mediated DNA recombination of the Prnp gene was detected in the peripheral blood of the CD21‐CrePrnpflox/− mice indicating that PrPC expression was not affected in the haematopoietic compartment (including lymphocytes) of these mice (Fig. 1a; presence of the 210‐bp ‘Prnpflox’ band and absence of ‘Prnpde‐flox’ band, lane 1). Further analysis of splenic CD21+ B lymphocytes by FACS showed similar, low levels of PrPC on cells from wild‐type (WT) mice and CD21‐CrePrnpflox/− mice (Fig. 1b). Together, these data demonstrate that efficient Cre‐mediated ablation of the Prnp gene had occurred in the FDC, but not B lymphocytes, of bone marrow‐reconstituted CD21‐CrePrnpflox/− mice. Immunohistochemical analysis of spleens from WT mice confirmed high levels of PrPC labelling on FDC networks (Fig. 1c, top panels). In contrast, FDC in spleens from CD21‐CrePrnpflox/− mice lacked PrPC expression, confirming that Cre‐mediated excision of the Prnp open reading frame had occurred (Fig. 1c, bottom panels). In addition to FDC, high levels of PrPC expression were also observed upon tyrosine hydroxylase+ sympathetic nerves in the spleens of WT control mice (Fig. 1d, upper panel). In the spleens of CD21‐CrePrnpflox/− mice, high levels of PrPC expression were also observed upon splenic nerves (Fig. 1d, lower panel). Morphometric analysis confirmed that the magnitude of the PrPC expression co‐localized upon the surfaces of tyrosine hydroxylase+ sympathetic nerves in the spleens of CD21‐Cre Prnpflox/− mice was not significantly different when compared with controls (Fig. 1e, open bars, P = 0·390). In contrast, the magnitude of the PrPC expression co‐localized upon the surfaces of FDC in the spleens of CD21‐Cre Prnpflox/− mice was substantially and significantly lower than that observed upon FDC from control mice (Fig. 1e, closed bars, P < 1·0 × 10−22). Taken together, these data confirm that in the spleens of the bone marrow‐reconstituted CD21‐Cre Prnpflox/− mice the Prnp ablation was specifically restricted to FDC.
PrPC expression by FDC has no role in FDC‐mediated organization of the lymphoid follicle
To understand the effects of PrPC ablation on FDC‐dependent organization of the B‐lymphocyte follicle, lymphoid tissue microarchitecture was assessed in spleens from mice with PrPC ablation specifically restricted to FDC and compared with tissues from WT and single transgenic controls. The FDC were immunolabelled with a variety of commonly used markers: CD21/35 (CR2/CR1) and complement component C4. Each of these showed no observable difference in their distribution in spleens from mice from each group (Fig. 2a). Similarly there were no apparent differences in the distribution of B and T lymphocytes and CD11c+ classical dendritic cells between the mouse lines (Fig. 2a). Additionally, no disruptions to the microarchitecture of the B‐lymphocyte follicles, T‐cell zones and marginal zones were noted (Fig 2a). In contrast to B cells, FDC in mice specifically express high levels of CD35 (CR1) (Fig. 2b). We therefore used anti‐CD35 immunolabelling to measure the number and area of FDC networks in spleens from each group of mice. No significant differences in the number or area of FDC networks in the spleen were found between mice with PrPC ablation specifically in FDC and controls (Fig. 2c). These data show that FDC‐specific PrPC ablation had no observable effect on the organization of the lymphoid tissue microarchitecture. These data suggest that PrPC on FDC does not have a role in the ability of these cells to induce and organize the development of the follicle structure.
Ablation of PrPC specifically in FDC has no effect on their ability to trap and retain immune complexes
The FDC's ability to trap and retain native antigen in the form of immune complexes is important for the development of effective humoral immune responses.10,12,56 The distribution, but not the amount, of antigen on the FDC surface and the stoichiometry of antibody : antigen interactions can affect the avidity of downstream humoral immune responses.57–59 As PrPC is found in membrane lipid rafts, it was hypothesized that the ablation of PrPC on the FDC surface may change the organization of surface membrane proteins, and indirectly, affect the ability of the FDC to initiate an efficient humoral immune response. The ability of FDC to trap and retain antigen in vivo was assessed by injecting pre‐formed PAP immune complexes. The retention of the PAP immune complexes on the FDC network was determined by the histological assessment of the association of peroxidase activity or rabbit immunoglobulin from the PAP complexes with FDC (CD35‐expressing cells). No differences were apparent in either the levels of peroxidase activity (Fig. 3a, upper panels) or the amount of rabbit immunoglobulin (Fig. 3a, lower panels) bound to the surfaces of FDC from mice from each group. Furthermore, morphometric analysis confirmed that no significant difference was observed in the mean number of PAP+ pixels detected on FDC networks in mice from each group (Fig. 3b, P = 0·977). These data show that FDC do not require the expression of PrPC to trap and retain immune complexes on their surfaces.
PrPC expression by FDC is dispensable for the induction of antigen‐specific antibody production and affinity maturation
We next determined whether the ablation of PrPC in FDC affected their ability to support B‐lymphocyte generation of high‐affinity, class‐switched immunoglobulin. Mice from each group were immunized with DNP‐KLH and serum levels of antigen‐specific immunoglobulin levels were compared. Seven days after primary immunization the titres of antigen‐specific IgM (Fig. 4a, P = 1) or total IgG (Fig. 4c, P > 0·07) detected in the sera were not significantly different between all of the mouse groups tested. This suggests that ablation of PrPC on FDC has no impact on the ability of the FDC to support an efficient primary antibody response within the germinal centre. At day 21 (7 days after booster immunization) mice with PrPC ablated on FDC showed significantly lower titres of IgM in comparison to WT controls (Fig 4b, P < 0·001). However, single transgenic control groups also had similarly reduced titres of IgM and therefore this reduction cannot be attributed to the loss of PrPC on the FDC and is more likely a result of subtle differences in the host genetic background. Titres of total antigen‐specific IgG at day 21 showed no significant differences between groups (Fig. 4d, P > 0·07). These data suggest that the ablation of PrPC in FDC does not significantly impact the efficiency of the germinal centre to support a secondary antibody response in immunized animals.
Serum levels of IgG subclasses were also compared to assess if mice with PrPC ablated on FDC showed any impairment in affinity maturation via the ability to class switch their immunoglobulin. Mice with PrPC ablation on FDC had significantly higher titres of IgG1 (Fig. 5a, P < 0·001) and IgG3 (Fig. 5d, P < 0·001). However, in both cases, the single transgenic control groups also showed similar differences indicating that this effect cannot be specifically attributed to the loss of PrPC on FDC. Levels of IgG2a and IgG2b (Fig. 5b, P > 0·065; Fig 5c, P > 0·09) did not differ significantly between mice from each group. Although some differences in IgG subclass titres were observed between groups, none of these differences were specific to mice with PrPC ablated on FDC. Taken together, these data show that ablation of PrPC specifically on FDC does not impair their ability to induce a primary and secondary humoral immune response and has no impact on the affinity maturation of antigen‐specific B lymphocytes in the follicle.
PrPC ablation does not affect FDC maturation
After immunization, FDC induce the formation of the GC and up‐regulate their expression of adhesion molecules and TLR4 to improve B‐lymphocyte–FDC contact and direct the sub‐class switching of B lymphocytes.1,12,20 We therefore next determined whether PrPC ablation affected the ability of the FDC to mature. Immunohistochemical analysis of spleens from immunized mice showed that FDC‐specific PrPC ablation showed no difference in their expression of adhesion molecules (ICAM and VCAM) or TLR4 when compared with WT mice or the single transgenic controls (Fig. 6a). Furthermore, morphometric analysis suggested that there was no significant difference in the magnitude of the CD35‐, TLR4‐, ICAM1‐ and VCAM‐specific immunostaining observed on the FDC networks of immunized WT and CD21‐Cre Prnpflox/− mice (Fig. 6b). These data suggest that PrPC expression by FDC is dispensable for their maturation.
Discussion
The gene that encodes for PrPC is highly conserved between mice and humans and is ubiquitously expressed in most cell types with expression of PrPC being found in all vertebrates. This would imply that expression of PrPC is directly or indirectly required for some vital cellular function. A definitive role for the high levels of PrPC expressed on the FDC remains to be established. In this study, we assessed FDC function in mice with PrPC ablation specifically restricted to FDC. The novelty of this study was that a cell‐specific knockout of PrPC using the Cre‐LoxP system was used to determine an in vivo, physiologically relevant function of PrPC expression on FDC. In the limited studies undertaken previously to assess the immune system in Prnp−/− mice no evidence of immunodeficiency had been found.60–63 However, studies so far have mainly involved in vitro challenge of Prnp−/− cell populations or in vivo studies carried out in unchallenged mice kept in pathogen‐free conditions. It remains possible that under these steady‐state conditions a functional role for PrPC within the immune system is hard to determine. For this reason, analysis of the effects of PrPC ablation specifically on FDC were carried out in in vivo models under both normal homeostatic conditions and following immunization.
In these studies, no effects on the development of the lymphoid follicle were found in mice with PrPC‐ablated FDC. Furthermore, these mice had no impairments in their ability to trap immune complexes on their surface and no defects in their ability to produce antigen‐specific antibodies or undergo affinity maturation. These data are consistent with previous studies showing that Prnp−/− mice are able to elicit effective antigen‐specific antibody responses following immunization with PrP.30,64,65 The FDC were also able to mature functionally in the GC with no observable impairments. Together these data show that PrPC expression on FDC is dispensable for their functional maturation and ability to maintain antigen‐specific antibody production and affinity maturation in the GC.
One hypothesized function of PrPC is in the formation of intercellular gap junctions. A loss of PrPC has been found to weaken gap junctions in the intestinal epithelial cell layer resulting in increased permeability of the mucosa.66 FDC networks are reported to be connected to each other and to surrounding B lymphocytes via gap junctions.67 In the analysis carried out in this study the development of FDC networks and the surrounding B‐lymphocyte follicle appeared to be normal, with no abnormalities in GC formation or downstream antibody responses. However, as the gap junctions themselves were not specifically analysed, the possibility still remains that they are weakened in mice with PrPC ablated in FDC. Another suggested role for PrPC is protection against oxidative stress. So it is plausible that a loss of PrPC may only show phenotypic characteristics in aged mice or conditions of oxidative stress. Furthermore, ultra‐structural studies of PrP‐deficient FDC in comparison to WT counterparts may be required to provide indications as to the precise function of PrPC on FDC.
Many studies investigating the function of PrPC in both the CNS and the immune system in various Prnp−/− mouse lines have similarly struggled to find a definitive functional role for PrPC expression. Although several functions have been proposed for PrPC within the CNS, many of these reported findings such as synaptic transmission, have little bearing on why cells of the immune system, and more specifically FDC, should express such high levels of this protein. Within the immune system, PrPC has been reported to have several potentially conflicting functions. In T lymphocytes, PrPC is found within the immunological synapse and co‐localizes with the T‐lymphocyte receptor (TCR) after TCR cross‐linking. Cross‐linking of this PrPC on T lymphocytes using anti‐PrP antibodies has been shown to stimulate T lymphocytes as measured via calcium flux.68 Others, in contrast, have suggested that anti‐PrP antibodies block T‐lymphocyte activation by concanavalin A, anti‐TCR and MHC peptide.63,69,70 These apparently contradicting data highlight the many difficulties encountered in determining the function of PrPC in the immune system.
In conclusion, data presented here show that PrPC expression is dispensable for the functional maturation of FDC and their ability to maintain antigen‐specific antibody responses and affinity maturation. As a consequence, the precise role of PrPC expression on the FDC remains elusive. Further studies are necessary to understand the biology of this highly conserved cellular protein both in the context of normal immune function and prion disease pathogenesis to better our knowledge of these processes.
Acknowledgments
We thank Barry Bradford, Bob Fleming, Nadia Tuzi, Irene McConnell, Fraser Laing, Simon Cumming and the Pathology Services Group (University of Edinburgh, UK) for helpful discussion and excellent technical support; Nathalie Uyttersprot (current address, Artemis Pharmaceuticals GmbH, Germany), Ari Waisman (Johannes Gutenberg University of Mainz, Germany) and Klaus Rajewsky (Harvard Medical School, Massachusettes, USA) for supplying the CD21‐cre mice; Jean Manson (University of Edinburgh, UK) for providing the Prnp−/− and PrPflox/flox mouse lines; and Herbert Baybutt (University of Edinburgh, UK) for help with statistical analyses using SPSS software. This research was supported by project (Grant numbers BB/526741‐1 and BBS/E/R/00001813) and institute strategic grant funding from the BBSRC.
Glossary
- AP
alkaline phosphatase
- CR
complement receptor
- DNP‐KLH
dinitrophenyl–keyhole limpet haemocyanin
- FDC
follicular dendritic cell
- GC
germinal centre
- ICAM
intercellular adhesion molecule
- mAb
monoclonal antibody
- PAP
peroxidase–anti‐peroxidase
- PrPC
cellular isomer of the prion protein
- TCR
T‐cell receptor
- TLR
Toll‐like receptor
- VCAM
vascular cell adhesion molecule
- WT
wild‐type
Disclosures
The authors declare no financial or commercial conflict of interests.
References
- 1.Heinen E, Bosseloir A, Bouzahzah F. Follicular dendritic cells: origin and function. Curr Top Microbiol Immunol. 1995;201:15–47. doi: 10.1007/978-3-642-79603-6_2. [DOI] [PubMed] [Google Scholar]
- 2.Wang X, Cho B, Suzuki K, Xu Y, Green JA, An J, Cyster JG. Follicular dendritic cells help establish follicle identity and promote B cell retention in germinal centers. J Exp Med. 2011;208:2497–510. doi: 10.1084/jem.20111449. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Kapasi ZF, Burton GF, Shultz LD, Tew JG, Szakal AK. Induction of functional follicular dendritic cell development in severe combined immunodeficiency mice. Influence of B and T cells. J Immunol. 1993;150:2648–58. [PubMed] [Google Scholar]
- 4.Kapasi ZF, Qin D, Kerr WG, Kosco‐Vilbois MH, Shultz LD, Tew JG, Szakal AK. Follicular dendritic cell (FDC) precursors in primary lymphoid tissues. J Immunol. 1998;160:1078–84. [PubMed] [Google Scholar]
- 5.Balogh P, Aydar Y, Tew JG, Szakal AK. Ontogeny of the follicular dendritic cell phenotype and function in the postnatal murine spleen. Cell Immunol. 2001;214:45–53. doi: 10.1006/cimm.2001.1874. [DOI] [PubMed] [Google Scholar]
- 6.Chaplin DD, Fu YX. Cytokine regulation of secondary lymphoid organ development. Curr Opin Immunol. 1998;10:289–97. doi: 10.1016/s0952-7915(98)80167-2. [DOI] [PubMed] [Google Scholar]
- 7.Victoratos P, Lagnel J, Tzima S, Alimzhanov MB, Rajewsky K, Pasparakis M, Kollias G. FDC‐specific functions of p55TNFR and IKK2 in the development of FDC networks and of antibody responses. Immunity. 2006;24:65–77. doi: 10.1016/j.immuni.2005.11.013. [DOI] [PubMed] [Google Scholar]
- 8.Krautler NJ, Kana V, Kranich J. Follicular dendritic cells emerge from ubiquitous perivascular precursors. Cell. 2012;150:194–206. doi: 10.1016/j.cell.2012.05.032. et al. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Qin D, Wu J, Vora KA, Ravetch JV, Szakal AK, Manser T, Tew JG. Fcγ receptor IIB on follicular dendritic cells regulates the B cell recall response. J Immunol. 2000;164:6268–75. doi: 10.4049/jimmunol.164.12.6268. [DOI] [PubMed] [Google Scholar]
- 10.Gray D, Skarvall H. B‐cell memory is short‐lived in the absence of antigen. Nature. 1988;336:70–3. doi: 10.1038/336070a0. [DOI] [PubMed] [Google Scholar]
- 11.Gray D, Kosco MH, Stockinger B. Novel pathways of antigen presentation for the maintenance of memory. Int Immunol. 1991;3:141–8. doi: 10.1093/intimm/3.2.141. [DOI] [PubMed] [Google Scholar]
- 12.Kosco MH, Pflugfelder E, Gray D. Follicular dendritic cell‐dependent adhesion and proliferation of B cells in vitro. J Immunol. 1992;148:2331–9. [PubMed] [Google Scholar]
- 13.Suzuki K, Grigorova I, Phan TG, Kelly LM, Cyster JG. Visualizing B cell capture of cognate antigen from follicular dendritic cells. J Exp Med. 2009;206:1485–93. doi: 10.1084/jem.20090209. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Roozendaal R, Carroll MC. Complement receptors CD21 and CD35 in humoral immunity. Immunol Rev. 2007;219:157–66. doi: 10.1111/j.1600-065X.2007.00556.x. [DOI] [PubMed] [Google Scholar]
- 15.Nielsen CH, Fischer EM, Leslie RGQ. The role of complement in the acquired immune response. Immunology. 2000;100:4–12. doi: 10.1046/j.1365-2567.2000.00009.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Videm V, Albrigtsen M. Soluble ICAM‐1 and VCAM‐1 as markers of endothelial activation. Scand J Immunol. 2008;67:523–31. doi: 10.1111/j.1365-3083.2008.02029.x. [DOI] [PubMed] [Google Scholar]
- 17.Kosco‐Vilbois MH, Bonnefoy JY, Chvatchko Y. The physiology of murine germinal center reactions. Immunol Rev. 1997;156:127–36. doi: 10.1111/j.1600-065x.1997.tb00964.x. [DOI] [PubMed] [Google Scholar]
- 18.Kopf M, Herren S, Wiles MV, Pepys MB, Kosco‐Vilbois MH. Interleukin 6 influences germinal center development and antibody production via a contribution of C3 complement component. J Exp Med. 1998;188:1895–906. doi: 10.1084/jem.188.10.1895. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Hase H, Kanno Y, Kojima M. BAFF/BLys can potentiate B‐cell selection with the B‐cel coreceptor complex. Blood. 2004;103:2257–65. doi: 10.1182/blood-2003-08-2694. et al. [DOI] [PubMed] [Google Scholar]
- 20.Suzuki K, Maruya M, Kawamoto S, Sitnik K, Kitamura H, Agace WW, Fagarasan S. The sensing of environmental stimuli by follicular dendritic cells promotes immunoglobulin A generation in the gut. Immunity. 2010;33:71–83. doi: 10.1016/j.immuni.2010.07.003. [DOI] [PubMed] [Google Scholar]
- 21.Kranich J, Krautler NJ, Heinen E. Follicular dendritic cells control engulfment of apoptotic bodies by secreting Mfge8. J Exp Med. 2008;205:1293–302. doi: 10.1084/jem.20071019. et al. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Ho J, Moir S, Kulik L. Role for CD21 in the establishment of an extracellular HIV reservoir in lymphoid tissues. J Immunol. 2007;178:6968–74. doi: 10.4049/jimmunol.178.11.6968. et al. [DOI] [PubMed] [Google Scholar]
- 23.Manson JC, Clarke AR, Hooper ML, Aitchison L, McConnell I, Hope J. 129/Ola mice carrying a null mutation in PrP that abolishes mRNA production are developmentally normal. Mol Neurobiol. 1994;8:121–7. doi: 10.1007/BF02780662. [DOI] [PubMed] [Google Scholar]
- 24.Brown KL, Stewart K, Ritchie DL, Mabbott NA, Williams A, Fraser H, Morrison WI, Bruce ME. Scrapie replication in lymphoid tissues depends on prion protein‐expressing follicular dendritic cells. Nat Med. 1999;5:1308–12. doi: 10.1038/15264. [DOI] [PubMed] [Google Scholar]
- 25.McCulloch L, Brown KL, Bradford BM, Hopkins J, Bailey M, Rajewsky K, Manson JC, Mabbott NA. Follicular dendritic cell‐specific prion protein (PrPC) expression alone is sufficient to sustain prion infection in the spleen. PLoS Pathog. 2011;7:e1002402. doi: 10.1371/journal.ppat.1002402. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Caughey B, Race RE, Chesebro B. Detection of prion protein mRNA in normal and scrapie‐infected tissues and cell lines. J Gen Virol. 1988;69:711–6. doi: 10.1099/0022-1317-69-3-711. [DOI] [PubMed] [Google Scholar]
- 27.Kretzschmar HA, Prusiner SB, Stowring LE, deArmond SJ. Scrapie prion proteins are synthesised in neurones. Am J Pathol. 1986;122:1–5. [PMC free article] [PubMed] [Google Scholar]
- 28.Brown HR, Goller NL, Rudelli RD, Mertz GS, Wolfe GC, Wisniewski HM, Robakis NK. The mRNA encoding the scrapie agent protein is present in a variety of non‐neuronal cells. Acta Neuropathol. 1990;80:1–6. doi: 10.1007/BF00294214. [DOI] [PubMed] [Google Scholar]
- 29.Ford MJ, Burton LJ, Morris RJ, Hall SM. Selective expression of prion protein in peripheral tissues of the adult mouse. Neuroscience. 2002;113:177–92. doi: 10.1016/s0306-4522(02)00155-0. [DOI] [PubMed] [Google Scholar]
- 30.Prusiner SB, Groth D, Serban A. Ablation of the prion protein (PrP) gene in mice prevents scrapie and facilitates production of anti‐PrP antibodies. Proc Natl Acad Sci USA. 1993;90:10608–12. doi: 10.1073/pnas.90.22.10608. et al. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Lasmézas CI. Putative functions of PrPc. Br Med Bull. 2003;66:61–70. doi: 10.1093/bmb/66.1.61. [DOI] [PubMed] [Google Scholar]
- 32.Prusiner SB, Scott MR, DeArmond SJ, Cohen FE. Prion protein biology. Cell. 1998;93:337–48. doi: 10.1016/s0092-8674(00)81163-0. [DOI] [PubMed] [Google Scholar]
- 33.Tobler I, Gaus SE, Deboer T. Altered circadian activity rhythms and sleep in mice devoid of prion protein. Nature. 1996;380:639–42. doi: 10.1038/380639a0. et al. [DOI] [PubMed] [Google Scholar]
- 34.Collinge J, Whittington MA, Sidle KCL, Smith CJ, Palmer MS, Clarke AR, Jefferys JGR. Prion protein is necessary for normal synaptic function. Nature. 1994;370:295–7. doi: 10.1038/370295a0. [DOI] [PubMed] [Google Scholar]
- 35.Nico PBC, de‐Paris F, Vinade ER. Altered behavioural response to acute stress in mice lacking cellular prion protein. Behav Brain Res. 2005;162:173–81. doi: 10.1016/j.bbr.2005.02.003. et al. [DOI] [PubMed] [Google Scholar]
- 36.Coitinho AS, Roesler R, Martins VR, Brentani RR, Izquierdo I. Cellular prion protein ablation impairs behavior as a function of age. NeuroReport. 2003;14:1375–9. doi: 10.1097/01.wnr.0000078541.07662.90. [DOI] [PubMed] [Google Scholar]
- 37.Walz R, Amaral OB, Rockenbach IC, Roesler R, Izquierdo I, Cavalheiro EA, Martins VR, Brentani RR. Increased sensitivity to seizures in mice lacking cellular prion protein. Epilepsia. 1999;40:1679–82. doi: 10.1111/j.1528-1157.1999.tb01583.x. [DOI] [PubMed] [Google Scholar]
- 38.Mouillet‐Richard S, Ermonval M, Chebassier C, Laplanche JL, Lehmann S, Launay JM, Kellermann O. Signal transduction through prion protein. Science. 2000;289:1925–8. doi: 10.1126/science.289.5486.1925. [DOI] [PubMed] [Google Scholar]
- 39.Spielhaupter C, Schätzl HM. PrPC directly interacts with proteins involved in signaling pathways. J Biol Chem. 2001;276:44604–12. doi: 10.1074/jbc.M103289200. [DOI] [PubMed] [Google Scholar]
- 40.Paitel E, Alves da Costa C, Vilette D, Grassi J, Checler F. Overexpression of PrPc triggers caspase 3 activation: potentiation by proteasome inhibitors and blockade by anti‐PrP antibodies. J Neurochem. 2002;83:1208–14. doi: 10.1046/j.1471-4159.2002.01234.x. [DOI] [PubMed] [Google Scholar]
- 41.Kurschner C, Morgan JI. The cellular prion protein (PrP) selectively binds to Bcl‐2 in the yeast two‐hybrid system. Mol Brain Res. 1995;30:165–8. doi: 10.1016/0169-328x(95)00013-i. [DOI] [PubMed] [Google Scholar]
- 42.Bounhar Y, Zhang Y, Goodyer CG, LeBlanc A. Prion protein protects human neurons against Bax‐mediated apoptosis. J Biol Chem. 2001;276:39145–9. doi: 10.1074/jbc.C100443200. [DOI] [PubMed] [Google Scholar]
- 43.Mitteregger G, Vosko M, Krebs B, Xiang W, Kohlmannsperger V, Nolting S, Hamann GF, Kretzschmar HA. The role of the octarepeat region in neuroprotective function of the cellular prion protein. Brain Pathol. 2007;17:174–83. doi: 10.1111/j.1750-3639.2007.00061.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Aude‐Garcia C, Villiers C, Candéias S, Garrel C, Bertrand C, Collin V, Marche P, Jouvin‐Marche E. Enhanced susceptibility of T lymphocytes to oxidative stress in the absence of the cellular prion protein. Cell Mol Life Sci. 2011;68:687–96. doi: 10.1007/s00018-010-0477-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Kraus M, Alimzhanov MB, Rajewsky N, Rajewsky K. Survival of resting mature B lymphocytes depends on BCR signaling via the Igα/β heterodimer. Cell. 2004;117:787–800. doi: 10.1016/j.cell.2004.05.014. [DOI] [PubMed] [Google Scholar]
- 46.Tuzi NL, Clarke AR, Bradford B, Aitchison L, Thomson V, Manson JC. Cre‐loxP mediated control of PrP to study transmissible spongiform encephalopathy diseases. Genesis. 2004;40:1–6. doi: 10.1002/gene.20046. [DOI] [PubMed] [Google Scholar]
- 47.Manson JC, Clarke AR, McBride PA, McConnell I, Hope J. PrP gene dosage determines the timing but not the final intensity or distribution of lesions in scrapie pathology. Neurodegeneration. 1994;3:331–40. [PubMed] [Google Scholar]
- 48.Farquhar CF, Somerville RA, Ritchie LA. Post‐mortem immunodiagnosis of scrapie and bovine spongiform encephalopathy. J Virol Methods. 1989;24:215–21. doi: 10.1016/0166-0934(89)90023-2. [DOI] [PubMed] [Google Scholar]
- 49.Inman CF, Rees LEN, Barker E, Haverson K, Stokes CR, Bailey M. Validation of computer‐assisted, pixel‐based analysis of multiple‐colour immunofluorescence histology. J Immunol Methods. 2005;302:156–67. doi: 10.1016/j.jim.2005.05.005. [DOI] [PubMed] [Google Scholar]
- 50.Liu Y‐J, Xu J, de Bouteiller O. Follicular dendritic cells specifically express the long CR2/CD21 isoform. J Exp Med. 1997;185:165–70. doi: 10.1084/jem.185.1.165. et al. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Takahashi K, Kozono Y, Waldschmidt TJ, Berthiaume D, Quigg RJ, Baron A, Holers VM. Mouse complement receptors type 1 (CR1;CD35) and type 2 (CR2;CD21): expression on normal B cell subpopulations and decreased levels during the development of autoimmunity in MRL/lpr mice. J Immunol. 1997;159:1557–69. [PubMed] [Google Scholar]
- 52.Tsoukas CD, Lambris JD. Expression of CR2/EBV receptors on human thymocytes detected by monoclonal antibodies. Eur J Immunol. 1988;18:1299–302. doi: 10.1002/eji.1830180823. [DOI] [PubMed] [Google Scholar]
- 53.June RA, Landay AL, Stefanik K, Lint TF, Spear GT. Phenotypic analysis of complement receptor 2+ T lymphocytes: reduced expression on CD4+ cells in HIV‐infected persons. Immunology. 1992;75:59–65. [PMC free article] [PubMed] [Google Scholar]
- 54.Sixbey J, Lemon S, Pagano J. A second site for Epstein–Barr virus shedding: the uterine cervix. Lancet. 1986;328:1122–4. doi: 10.1016/s0140-6736(86)90531-3. [DOI] [PubMed] [Google Scholar]
- 55.Andrasfalvy M, Prechl J, Hardy T, Erdei A, Bajtay Z. Mucosal type mast cells express complement receptor type 2 (CD21) Immunol Lett. 2002;82:29–34. doi: 10.1016/s0165-2478(02)00015-9. [DOI] [PubMed] [Google Scholar]
- 56.Kosco‐Vilbois MH. Are follicular dendritic cells really good for nothing? Nat Rev Immunol. 2003;3:764–9. doi: 10.1038/nri1179. [DOI] [PubMed] [Google Scholar]
- 57.Oda M, Uchiyama S, Noda M. Effects of antibody affinity and antigen valence on molecular forms of immune complexes. Mol Immunol. 2009;47:357–64. doi: 10.1016/j.molimm.2009.09.009. et al. [DOI] [PubMed] [Google Scholar]
- 58.Keşmir C, De Boer RJ. A spatial model of germinal center reactions: cellular adhesion based sorting of B cells results in efficient affinity maturation. J Theor Biol. 2003;222:9–22. doi: 10.1016/s0022-5193(03)00010-9. [DOI] [PubMed] [Google Scholar]
- 59.Vora KA, Ravetch JV, Manser T. Amplified follicular immune complex deposition in mice lacking the Fc receptor γ‐chain does not alter maturation of the B cell response. J Immunol. 1997;159:2116–24. [PubMed] [Google Scholar]
- 60.Genoud N, Behrens A, Miele G, Robay D, Heppner FL, Freigang S, Aguzzi A. Disruption of Doppel prevents neurodegeneration in mice with extensive Prnp deletions. Proc Natl Acad Sci USA. 2004;101:4198–203. doi: 10.1073/pnas.0400131101. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.Bueler H, Fischer M, Lang Y. Normal development and behaviour of mice lacking the neuronal cell‐surface PrP protein. Nature. 1992;356:577–82. doi: 10.1038/356577a0. et al. [DOI] [PubMed] [Google Scholar]
- 62.Ballerini C, Gourdain P, Bachy V. Functional implication of cellular prion protein in antigen‐driven interactions between T cells and dendritic cells. J Immunol. 2006;176:7254–62. doi: 10.4049/jimmunol.176.12.7254. et al. [DOI] [PubMed] [Google Scholar]
- 63.Kubosaki A, Yusa S, Nasu Y. Distribution of cellular isoform of prion protein in T lymphocytes and bone marrow, analyzed by wild‐type and prion protein gene‐deficient mice. Biochem Biophys Res Commun. 2001;282:103–7. doi: 10.1006/bbrc.2001.4538. et al. [DOI] [PubMed] [Google Scholar]
- 64.Williamson RA, Peretz D, Smorodinsky N. Circumventing tolerance to generate autologous monoclonal antibodies to the prion protein. Proc Natl Acad Sci USA. 1996;93:7279–82. doi: 10.1073/pnas.93.14.7279. et al. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65.Khalili‐Shirazi A, Quaratino S, Londei M. Protein conformation significantly influences immune responses to prion protein. J Immunol. 2005;174:3256–63. doi: 10.4049/jimmunol.174.6.3256. et al. [DOI] [PubMed] [Google Scholar]
- 66.Petit CSV, Barreau F, Besnier L. Requirement of cellular prion protein for intestinal barrier function and mislocalization in patients with inflammatory bowel disease. Gastroenterology. 2012;143:122–32. doi: 10.1053/j.gastro.2012.03.029. et al. [DOI] [PubMed] [Google Scholar]
- 67.Krenacs T, van Dartel M, Lindhout E, Rosendaal M. Direct cell/cell communication in the lymphoid germinal center: connexin43 gap junctions functionally couple follicular dendritic cells to each other and to B lymphocytes. Eur J Immunol. 1997;27:1489–97. doi: 10.1002/eji.1830270627. [DOI] [PubMed] [Google Scholar]
- 68.Stuermer CAO, Langhorst MF, Wiechers MF, Legler DF, Von Hanwehr SH, Guse AH, Plattner H. PrPc capping in T cells promotes its association with the lipid raft proteins reggie‐1 and reggie‐2 and leads to signal transduction. FASEB J. 2004;18:1731–3. doi: 10.1096/fj.04-2150fje. [DOI] [PubMed] [Google Scholar]
- 69.Cashman NR, Loertscher R, Nalbantoglu J, Shaw I, Kascsak RJ, Bolton DC, Bendheim PE. Cellular isoform of the scrapie agent protein participates in lymphocyte activation. Cell. 1990;61:185–92. doi: 10.1016/0092-8674(90)90225-4. [DOI] [PubMed] [Google Scholar]
- 70.Li R, Liu D, Zanusso G. The expression and potential function of cellular prion protein in human lymphocytes. Cell Immunol. 2001;207:49–58. doi: 10.1006/cimm.2000.1751. et al. [DOI] [PubMed] [Google Scholar]